Education
About Us
Working with TipRanks
Follow Us
Opthea Limited (AU:OPT)
ASX:OPT
OPT Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.34 - AU$1.17
Previous CloseN/A
Volume897.04K
Average Volume (3M)3.89M
Market Cap
$738.77M
Enterprise ValueAU$279.69M
Total Cash (Recent Filing)$12.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Aug 28, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding1,231,287,400
10 Day Avg. Volume0
30 Day Avg. Volume3,894,609
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1222.82
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.24K
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
AU$0.52Price Target Upside-12.57% Downside
Rating ConsensusHold
Number of Analyst Covering3
---
Options Prices
Currently, No data available
---
Ownership Overview
0.02%
Insiders
2.76%
Mutual Funds
― Other Institutional Investors
95.70% Public Companies and
Individual Investors
OPT FAQ
What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest share price was AU$0.34 and its highest was AU$1.17 in the past 12 months.
What is Opthea Limited’s market cap?
Opthea Limited’s market cap is $738.77M.
When is Opthea Limited’s upcoming earnings report date?
Opthea Limited’s upcoming earnings report date is Aug 28, 2025 which is in 147 days.
How were Opthea Limited’s earnings last quarter?
Opthea Limited released its earnings results on Feb 27, 2025. The company reported -AU$0.176 earnings per share for the quarter, missing the consensus estimate of -AU$0.026 by -AU$0.151.
Is Opthea Limited overvalued?
According to Wall Street analysts Opthea Limited’s price is currently Overvalued.
Does Opthea Limited pay dividends?
Opthea Limited does not currently pay dividends.
What is Opthea Limited’s EPS estimate?
Opthea Limited’s EPS estimate is -0.06.
How many shares outstanding does Opthea Limited have?
Opthea Limited has 1,231,287,400 shares outstanding.
What happened to Opthea Limited’s price movement after its last earnings report?
Opthea Limited reported an EPS of -AU$0.176 in its last earnings report, missing expectations of -AU$0.026. Following the earnings report the stock price went up 2.674%.
Which hedge fund is a major shareholder of Opthea Limited?
Currently, no hedge funds are holding shares in AU:OPT
---
Opthea Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.52 (-12.57% Downside)
AU$0.52 (-12.57% Downside)
Blogger Sentiment
Bullish
AU:OPT Sentiment 89%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
---
OPT Stock 12 Month Forecast
Average Price Target
AU$0.52
▼(-12.57% Downside)
Technical Analysis
Biotron Limited
―
Imugene Limited
―
Paradigm Biopharmaceuticals Ltd.
―
PYC Therapeutics Limited
―
Race Oncology Ltd.
―
Best Analysts Covering OPT
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+46.67%
downgraded a sell rating 2 days ago
Copying Thomas Wakim's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +46.67% per trade.
---